LS
Liora Schultz
Columbia University
Research areas: Medicine · Oncology · CAR-T cell therapy research · Acute Lymphoblastic Leukemia research · Immunotherapy and Immune Responses
0000-0001-9512-7597
Employment
-
Columbia University Associate Professor, Director of Pediatric Cell Therapy2025 - Present
Education
Education history is unavailable.
Projects & Funding
-
Using a T-cell receptor like antibody to target FOXP3+ T regulatory cells St. Baldrick's Foundation2016 - 2019
-
Targeting AML with Genetically Modified CD33 Specific T-cells St. Baldrick's Foundation2014 - 2015
-
Markit Fellow - Targeting AML with Genetically Modified CD33 Specific T-cells St. Baldrick's Foundation2012 - 2014
Publications (32)
- Tracking B-cell depletion and reconstitution using next-generation immunosequencing Save
- Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia Save
- Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers Save
- LocaTIAN, locaTIAN, locaTIAN Save
- Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL Save
- Access to CARe: A Narrative of Real‐World Medical Decision‐Making to Access Chimeric Antigen Receptor (CAR) T‐Cell Therapy in Children, Adolescents, and Young Adults Save
- Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults Save
- INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities Save
- INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia Save
- Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting Save
- Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD Save
- Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia Save
- Outcomes of Hispanic and non-Hispanic White pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel Save
- Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report Save
- CD81 costimulation skews CAR transduction toward naive T cells Save
- Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. Save
- Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement Save
- Summary of COVID‐19 clinical practice adjustments across select institutions Save
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Save
- HLA-haplotype loss after TCRalphabeta/CD19-depleted haploidentical HSCT. Save